Zhao Xiaohua, Wang Shan, Sun Wenbao
Department of Neurology, The People's Hospital of Shouguang, Weifang, Shandong 262700, P.R. China.
Department of General Surgery, Shouguang Hospital of TCM, Weifang, Shandong 262700, P.R. China.
Exp Ther Med. 2020 Sep;20(3):2218-2226. doi: 10.3892/etm.2020.8920. Epub 2020 Jun 22.
Expression of miR-28-3p in patients with Alzheimer's disease (AD) before and after treatment and clinical value of miR-28-3p were determined. There were three groups: 68 AD patients treated with donepezil combined with basic therapy in The People's Hospital of Shouguang collected as an AD group, 70 patients with mild cognitive impairment (MCI) as an MCI group, and 75 healthy people as a normal group. Serum miR-28-3p was detected by qRT-PCR. The Montreal cognitive assessment scale (MoCA), mini mental state examination scale (MMSE), activities of daily living scale (ADL) and homocysteine (Hcy) were adopted to assess patients before and after treatment. miR-28-3p in normal group was significantly lower than that in other two groups, and miR-28-3p in MCI group was significantly lower than that in AD group (P<0.001). miR-28-3p correlated with the course and severity of patients. miR-28-3p in AD group after treatment was significantly lower than that before treatment (P<0.001). ADL and Hcy of AD patients after treatment were significantly lower than before treatment (P<0.05), and MMSE and MoCA after treatment were significantly higher than before treatment (P<0.05). Before and after treatment, miR-28-3p was significantly positively correlated with ADL score and Hcy level, but negatively correlated with MMSE score and MoCA score. Analysis of the working characteristic curve of the patients indicated that miR-28-3p can be used for diagnosis of AD patients. Donepezil therapy may reduce miR-28-3p level to alleviate the symptoms of AD patients, and miR-28-3p level can be used as an early diagnosis and prognosis evaluation of AD patients.
测定了阿尔茨海默病（AD）患者治疗前后miR-28-3p的表达情况及其临床价值。分为三组：寿光市人民医院收治的68例接受多奈哌齐联合基础治疗的AD患者作为AD组，70例轻度认知障碍（MCI）患者作为MCI组，75例健康人作为正常组。采用qRT-PCR检测血清miR-28-3p。采用蒙特利尔认知评估量表（MoCA）、简易精神状态检查表（MMSE）、日常生活活动量表（ADL）和同型半胱氨酸（Hcy）对患者治疗前后进行评估。正常组miR-28-3p显著低于其他两组，MCI组miR-28-3p显著低于AD组（P<0.001）。miR-28-3p与患者病程及严重程度相关。AD组治疗后miR-28-3p显著低于治疗前（P<0.001）。AD患者治疗后ADL和Hcy显著低于治疗前（P<0.05），MMSE和MoCA显著高于治疗前（P<0.05）。治疗前后，miR-28-3p与ADL评分和Hcy水平呈显著正相关，但与MMSE评分和MoCA评分呈负相关。对患者的工作特征曲线分析表明，miR-28-3p可用于AD患者的诊断。多奈哌齐治疗可能降低miR-28-3p水平以缓解AD患者症状，且miR-28-3p水平可作为AD患者早期诊断及预后评估指标。
